Barrow researchers make breakthrough on immune system and brain tumors

Key points
- The large, two-part study, led by Barrow research fellow Sergiy Kushchayev, MD under the guidance of Dr.
- What the researchers discovered was that immune cells of the brain and of the blood exhibit massive rearrangements when interacting with a malignant glioma under treatment.
- "This is the first time that researchers have conducted a regional tissue study of the brain and a malignant glioma to show that these immune cells do not aggregate or behave in the same way in their respective areas of the brain," says Dr.
- "This means that effective treatment in one area of the brain may not be effective in another area.
In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat. The large, two-part study, led by Barrow research fellow Sergiy Kushchayev, MD under the guidance of Dr. Mark Preul, Director of Neurosurgery Research, was published in the Sept. 14 issue of Cancer Management and Research. The study explores the effects of immunotherapy on malignant gliomas, cancerous brain tumors that typically have a poor prognosis.
What the researchers discovered was that immune cells of the brain and of the blood exhibit massive rearrangements when interacting with a malignant glioma under treatment. Essentially, the study demonstrates that the complex immune system reacts differently in different brain tissues and different regions of the brain, including tumors.
"This is the first time that researchers have conducted a regional tissue study of the brain and a malignant glioma to show that these immune cells do not aggregate or behave in the same way in their respective areas of the brain," says Dr. Preul.
"This means that effective treatment in one area of the brain may not be effective in another area. In fact, it could even cause other regions of the tumor to become worse."
The results of the study provide important insight into why clinical trials involving immunotherapies on glioma patients may not be working.
###
Source: St. Joseph's Hospital and Medical Center
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsU-M researchers find protein that may signal more aggressive prostate cancers
University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer. Biomarkers in the body are analogous to the warning lights in…
14 April 2015
NewsResearchers find new approach to treat drug-resistant HER2-positive breast cancer
Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy. Using human cell lines of the HER2-positive breast cancer subtype,…
10 April 2015
NewsUTSW researchers lead collaborative charge to uncover genetic diversity of pancreatic cancer
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap…






